Novo Nordisk shares slide 6% after weight loss drug trial disappoints
Novo Nordisk shares declined on Monday after the company reported that its next-generation weight-loss drug, CagriSema, ...
Yahoo Finance8d
Novo Nordisk stock slides Monday on second-generation GLP-1 data
Novo Nordisk (NVO) stock was down more than 8% Monday morning after the Danish drugmaker shared new data on its next-generation GLP-1 drug, CagriSema. The drug, a mix of cagrilintide and ...
Yahoo Finance6d
Roche signs $5.3 billion deal with Danish obesity drugmaker, Novo Nordisk stock slides 4%
Meanwhile, Novo Nordisk's stock was hit, sliding 4%, and Eli Lilly's stock was down just under 1%. The impact to Novo's stock is largely due to the CagriSema news earlier this week, along with the ...